MARKET

SWKH

SWKH

SWK Holdings
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.29
-0.14
-1.01%
Opening 11:13 01/20 EST
OPEN
13.40
PREV CLOSE
13.42
HIGH
13.60
LOW
12.92
VOLUME
8.16K
TURNOVER
--
52 WEEK HIGH
16.24
52 WEEK LOW
6.12
MARKET CAP
169.91M
P/E (TTM)
18.38
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Enteris BioPharma to Host Webinar on Strategies for Initiating Phase 1 Clinical Development with Limited API
, /PRNewswire/ -- , a biotechnology company developing innovative drug products built around its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), announced that the company will host a webinar, ti...
PR Newswire - PRF · 01/12 13:30
Enteris BioPharma to Host Webinar on Strategies for Initiating Phase 1 Clinical Development with Limited API
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), announced that the company will host a webinar, titled "Strategies for Entering Phase 1 Clinical Development with Limited API Quantities." The event is scheduled for Tuesday, January 19, 2021 at 1:30 p.m., ET, and will be co-hosted by Thomas Daggs, MBA, Enteris' Senior Director Product Development and Quality Control, and Angelo Consalvo, Enteris' Director Manufacturing.
PR Newswire · 01/12 13:30
Enteris Biopharma sees growth opportunities in 2021 with potential partnerships in the works
Biotechnology company Enteris BioPharma, wholly owned subsidiary of SWK Holdings ([[SWKH]] +0.2%), forecasts growth opportunities this year and says that it will actively pursue partnership discussions with companies seeking US domestic CDMO capabilities.Will
Seekingalpha · 01/07 18:14
Enteris BioPharma Highlights 2020 Achievements and 2021 Outlook
, /PRNewswire/ --
PR Newswire - PRF · 01/07 13:00
Enteris BioPharma Highlights 2020 Achievements and 2021 Outlook
Rajiv Khosla, Ph.D., named Chief Executive Officer
PR Newswire · 01/07 13:00
Flowonix Medical, Inc. and SWK Holdings Corporation Announce Closing of $33 Million Financing
, /PRNewswire/ -- Flowonix Medical, Inc., a medical device company focused on providing advanced, implantable drug delivery solutions and SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small and mid-...
PR Newswire - PRF · 01/04 13:07
SWK Holdings' subsidiary receives second milestone payment from Cara
SWK Holdings' (SWKH) wholly-owned subsidiary, Enteris BioPharma received a second milestone payment of $2.5M from Cara Therapeutics (CARA) with regards the license agreement for Peptelligence oral formulation technology utilized in Oral KORSUVA.According
Seekingalpha · 12/24/2020 12:55
SWK Holdings' Subsidiary, Enteris BioPharma, Receives Second Milestone Payment from Cara Therapeutics
, /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that its wholly-owned subsidiary, Enteris BioPharma, received a secon...
PR Newswire - PRF · 12/24/2020 12:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SWKH. Analyze the recent business situations of SWK Holdings through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SWKH stock price target is 23.00 with a high estimate of 23.00 and a low estimate of 23.00.
EPS
Institutional Holdings
Institutions: 35
Institutional Holdings: 11.19M
% Owned: 87.53%
Shares Outstanding: 12.79M
TypeInstitutionsShares
Increased
8
225.43K
New
7
3.25K
Decreased
14
171.93K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Corporate Financial Services
-0.83%
Banking Services
-0.69%
Key Executives
Chairman/Chief Executive Officer/Director
Winston Black
Chief Financial Officer
Charles Jacobson
Independent Director
D. Blair Baker
Independent Director
Aaron Fletcher
Independent Director
Christopher Haga
Independent Director
Edward Stead
Independent Director
Michael Weinberg
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SWKH
SWK Holdings Corporation is a healthcare capital provider. The Company offers financing solutions to a range of life science companies, institutions and inventors. The Company comprises of two segments Finance Receivables and Pharmaceutical Development. The Company's focus is on monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. The Company, through its subsidiary SWK Advisors LLC, provides non-discretionary investment advisory services to institutional clients in separately managed accounts to similarly invest in life science finance. It focuses to fund transactions through its own working capital, as well as by building its asset management business by raising additional third party capital to be invested alongside its capital.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of SWK Holdings Corp stock information, including NASDAQ:SWKH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SWKH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SWKH stock methods without spending real money on the virtual paper trading platform.